Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose cyclophosphamide for graft-versus-host disease prophylaxis in elderly allogeneic transplant recipients
2012-004118-33Phase 2Active
- Sponsor
- ASST Grande Ospedale Metropolitano Niguarda
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in graft-versus-host disease (GVHD), sponsored by ASST Grande Ospedale Metropolitano Niguarda. Primary endpoint: Non-relapse mortality at 90 days. Started Dec 2012; status: active.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2012-004118-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004118-33.